Navneet Singh: Ensuring global access to the 3 ‘A’s of treatment
Navneet Singh, Thoracic Medical Oncologist at the Postgraduate Institute of Medical Education and Research, shared a post on LinkedIn by ESMO, adding:
“The ultimate goal is that patients; no matter where in the world they are based and no matter what disease/disorder they have been diagnosed with; get the 3 ‘A’s related to treatment namely
- Access,
- to the most Appropriate treatment
- which is also simultaneously Affordable.
The ESMO – European Society for Medical Oncology study gives a very important perspective in context of patients with cancer. Concerted and sustained efforts are needed on a global scale to provide patients and their caregivers with Affordable Access to Appropriate oncology care.
Quoting ESMO’s post:
“The results of the ‘ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update’ are now available in Annals Of Oncology.
This is the largest-ever survey of its type addressing the critical issue of accessibility to Cancer Medicines, focusing on the availability and affordability of safe and effective therapies for patients with cancer.
As medicine availability directly impacts clinicians’ daily practice and their ability to provide care, this study confirms ESMO’s commitment to ensuring timely and optimal treatment opportunities for patients with cancer.”
Authors: Jean-Yves Blay, Giuseppe Curigliano, Navneet Singh, Sara Cecilia Altuna Mujica, Dario Trapani et al.
More posts featuring Navneet Singh and ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023